Back to top

Analyst Blog

KaloBios Pharmaceuticals, Inc. (KBIO - Snapshot Report) announced the pricing of its underwritten public offering of its common stock. The company is looking to issue 7.5 million shares at $4 per share. KaloBios expects net proceeds of $27.9 million through this offering.

Underwriters have been granted an option to purchase an additional 1.1 million shares of KaloBios’ common stock, with a 30-day window to do so.

KaloBios intends to utilize the net proceeds from the public offering primarily for the development of its pipeline. The company also has plans to use the net proceeds for working capital and other general corporate purposes. Cash and cash equivalents at the end of Jun 30, 2013 were roughly $19.5 million.

We are encouraged by KaloBios’ progress on its pipeline. KB001-A, a second generation, anti-TTSS antibody, is currently in a phase II study for the treatment of chronic Pa infections in cystic fibrosis (CF) patients. While KaloBios has orphan drug status for KB001-A in the EU, the U.S. Food and Drug Administration (FDA) has completed its review for the same and has asked for additional information.

After the completion of the ongoing phase II CF study, KaloBios will provide the FDA with additional data. Enrollment is expected to complete in mid-2014 with top-line results due in the fourth quarter of 2014.

KaloBios has completed enrollment of patients in a phase II study on another candidate, KB003. KB003 is being studied for the treatment of severe asthma. KaloBios anticipates top-line results in the first quarter of 2014.

KaloBios is currently conducting a phase I study on its anti-EphA3 mAb, KB004, for the treatment of hematologic malignancies. After top-line data from this study is obtained (in the fourth quarter of 2013), KaloBios plans to start the phase II expansion phase of the study in acute myeloid leukemia and myelodysplastic syndrome.

KaloBios currently carries a Zacks Rank #3 (Hold). Companies that look well-positioned include Roche Holding (RHHBY - Analyst Report), Questcor Pharmaceuticals Inc.  and Actelion Ltd. (ALIOF). All three carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%